Literature DB >> 17665259

Clinical features and quality of life in patients with different phenotypes of Crohn's disease of the ileal pouch.

Bo Shen1, Victor W Fazio, Feza H Remzi, Ana E Bennett, Ian C Lavery, Rocio Lopez, Aaron Brezinski, Kerry K Sherman, Marlene L Bambrick, Bret A Lashner.   

Abstract

PURPOSE: Crohn's disease of the pouch can occur in patients with colectomy and ileal pouch-anal anastomosis performed for ulcerative colitis. The clinical features of inflammatory, fibrostenotic, and fistulizing Crohn's disease have not been characterized.
METHODS: A total of 73 eligible patients with Crohn's disease of the pouch, who were seen in the Pouchitis Clinic, were enrolled: 25 with inflammatory Crohn's disease, 17 with fibrostenotic Crohn's disease, and 31 with fistulizing Crohn's disease. The clinical phenotypes of Crohn's disease were based on a combined assessment of clinical, endoscopic, radiographic, and histologic features. Clinical symptoms, endoscopic and histologic features, and health-related quality-of-life scores were assessed.
RESULTS: Demographic and clinical features, including preoperative and postoperative parameters, were similar between the three phenotypes of Crohn's disease of the pouch. The use of nonsteroidal anti-inflammatory drugs, neuropsychiatric drugs, antidiarrheal agents, and Crohn's disease medicines was not different between the three groups. Predominant symptoms, as expected, were significantly different between the three phenotypes: diarrhea and/or pain in 92 percent of patients with inflammatory Crohn's disease, obstructive symptoms in 64.7 percent of patients with fibrostenotic Crohn's disease, and fistular drainage in 51.6 percent of those with fistulizing Crohn's disease (P < 0.0001). There was no statistical difference in quality-of-life scores between the three phenotypes, adjusted for disease activity. There was no significant correlation between quality-of-life and symptom scores in any of the three groups. Although not statistically significant, patients with fistulizing Crohn's disease (16.1 percent) tended to have an increased risk for pouch failure compared with inflammatory (8 percent) or fibrostenotic (5.9 percent) Crohn's disease.
CONCLUSIONS: Predominant symptoms were different in clinical phenotypes of Crohn's disease. Each of the three phenotypes of Crohn's disease similarly affected quality-of-life. Fistulizing Crohn's disease may be associated with a higher risk for pouch failure.

Entities:  

Mesh:

Year:  2007        PMID: 17665259     DOI: 10.1007/s10350-007-0284-8

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  16 in total

1.  Pre-colectomy appendectomy and risk for Crohn's disease in patients with ileal pouch-anal anastomosis.

Authors:  Zhaoxiu Liu; Haiyan Lu; Ravi P Kiran; Runzhou Ni; Feza H Remzi; Bo Shen
Journal:  J Gastrointest Surg       Date:  2012-04-24       Impact factor: 3.452

2.  Utility of fecal and serum anti-Saccharomyces cerevisiae antibodies in the diagnosis of Crohn's disease-like condition of the pouch.

Authors:  Linda Y Tang; Hui Cai; Udayakumar Navaneethan; James H Boone; Sarah J Rhodes; Lauren Moore; Hyunjin Rho; Carol de La Motte; Elaine Queener; Bo Shen
Journal:  Int J Colorectal Dis       Date:  2012-03-20       Impact factor: 2.571

3.  Family history of Crohn's disease is associated with an increased risk for Crohn's disease of the pouch.

Authors:  Bo Shen; Feza H Remzi; Jeffrey P Hammel; Bret A Lashner; Charles L Bevins; Ian C Lavery; Jan Wehkamp; Victor W Fazio
Journal:  Inflamm Bowel Dis       Date:  2009-02       Impact factor: 5.325

4.  The Incidence and Definition of Crohn's Disease of the Pouch: A Systematic Review and Meta-analysis.

Authors:  Edward L Barnes; Bharati Kochar; Hilary R Jessup; Hans H Herfarth
Journal:  Inflamm Bowel Dis       Date:  2019-08-20       Impact factor: 5.325

5.  Pouch-Related Symptoms and Quality of Life in Patients with Ileal Pouch-Anal Anastomosis.

Authors:  Edward L Barnes; Hans H Herfarth; Robert S Sandler; Wenli Chen; Elizabeth Jaeger; Van M Nguyen; Amber R Robb; Michael D Kappelman; Christopher F Martin; Millie D Long
Journal:  Inflamm Bowel Dis       Date:  2017-07       Impact factor: 5.325

6.  Is pyloric gland metaplasia in ileal pouch biopsies a marker for Crohn's disease?

Authors:  Shuchi Agarwal; Arthur F Stucchi; Kleanthis Dendrinos; Sandra Cerda; Michael J O'Brien; James M Becker; Timothy Heeren; Francis A Farraye
Journal:  Dig Dis Sci       Date:  2013-03-30       Impact factor: 3.199

7.  Transmural inflammation is not pathognomonic for Crohn's disease of the pouch.

Authors:  Zhao-xiu Liu; Tom Deroche; Feza H Remzi; Jefferey P Hammel; Victor W Fazio; Run-zhou Ni; John R Goldblum; Bo Shen
Journal:  Surg Endosc       Date:  2011-06-10       Impact factor: 4.584

8.  Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort.

Authors:  Martin Gregory; Kimberly N Weaver; Patrick Hoversten; Stephen Bradley Hicks; Devin Patel; Matthew A Ciorba; Alexandra M Gutierrez; Poonam Beniwal-Patel; Sowmya Palam; Gaurav Syal; Hans H Herfarth; George Christophi; Laura Raffals; Edward L Barnes; Parakkal Deepak
Journal:  Inflamm Bowel Dis       Date:  2019-08-20       Impact factor: 5.325

9.  Clinical significance of indefinite for dysplasia on pouch biopsy in patients with underlying inflammatory bowel disease.

Authors:  Zhao-Xiu Liu; Xiu-Li Liu; Deepa T Patil; Lei Lian; Ravi P Kiran; Feza H Remzi; Run-Zhou Ni; Bo Shen
Journal:  J Gastrointest Surg       Date:  2011-11-29       Impact factor: 3.452

10.  Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes.

Authors:  Sasha Taleban; Kathleen O Stewart; Darrick K Li; Prashant Singh; Darrell S Pardi; Holly C Sturgeon; Vijay Yajnik; Ramnik J Xavier; Ashwin N Ananthakrishnan; Hamed Khalili
Journal:  Dig Dis Sci       Date:  2016-05-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.